TheraRadar
← Back
Data updated: May 24, 2026

Sun Pharma

Generics
CardiovascularImmunologyDermatology Execution: Needs Improvement

Sun Pharma is a generic drug manufacturer focused on Cardiovascular, Immunology, Dermatology. Key products include DRIZALMA SPRINKLE.

1958
Since
373
Drugs
-
Trials
4
New Drugs (2yr)
Modality:
20 Small Molecules
Novel Drugs (2020-2024):
2 Novel Approvals 1 First-in-Class

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
BYNFEZIA PEN NDA
2024-09-27
octreotide acetate
Acromegaly
LEQSELVI NDA
2024-07-25
deuruxolitinib phosphate
Alopecia Areata

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 28%
24 drugs Phase 3: 7 Phase 2: 1
Immunology 20%
5 drugs Phase 3: 16 Phase 2: 14 Phase 1: 6
Dermatology 18%
11 drugs Phase 3: 3 Phase 2: 6 Phase 1: 26
Oncology 18%
12 drugs Phase 3: 3 Phase 2: 5 Phase 1: 17
Neurology 16%
16 drugs Phase 2: 1 Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

29
Phase 3
27
Phase 2
50
Phase 1

Phase 3 Readout Calendar Pro

3 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2028
TILD sub-cutaneous (SC) injection
Psoriatic Arthritis
Estimated · fresh NCT04991116
Q1 2026
Tildrakizumab 100 mg
Moderate to Severe Genital Psoriasis
Completed · awaiting NCT06611163
Q2 2025
TILD
Active Psoriatic Arthritis
Completed · awaiting NCT04314531

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 3 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/27 completed
  • • Speed: 43 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges